1. Home
  2. LEXX vs VCIG Comparison

LEXX vs VCIG Comparison

Compare LEXX & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • VCIG
  • Stock Information
  • Founded
  • LEXX 2004
  • VCIG 2013
  • Country
  • LEXX Canada
  • VCIG Malaysia
  • Employees
  • LEXX N/A
  • VCIG N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • VCIG Diversified Commercial Services
  • Sector
  • LEXX Health Care
  • VCIG Consumer Discretionary
  • Exchange
  • LEXX Nasdaq
  • VCIG Nasdaq
  • Market Cap
  • LEXX 23.9M
  • VCIG 22.5M
  • IPO Year
  • LEXX N/A
  • VCIG 2023
  • Fundamental
  • Price
  • LEXX $0.82
  • VCIG $6.32
  • Analyst Decision
  • LEXX Strong Buy
  • VCIG
  • Analyst Count
  • LEXX 1
  • VCIG 0
  • Target Price
  • LEXX $4.00
  • VCIG N/A
  • AVG Volume (30 Days)
  • LEXX 1.3M
  • VCIG 325.9K
  • Earning Date
  • LEXX 11-25-2025
  • VCIG 10-06-2025
  • Dividend Yield
  • LEXX N/A
  • VCIG N/A
  • EPS Growth
  • LEXX N/A
  • VCIG N/A
  • EPS
  • LEXX N/A
  • VCIG 162.63
  • Revenue
  • LEXX $615,923.00
  • VCIG $32,903,041.00
  • Revenue This Year
  • LEXX $46.98
  • VCIG N/A
  • Revenue Next Year
  • LEXX $17.26
  • VCIG N/A
  • P/E Ratio
  • LEXX N/A
  • VCIG $0.04
  • Revenue Growth
  • LEXX 49.85
  • VCIG 24.77
  • 52 Week Low
  • LEXX $0.77
  • VCIG $6.01
  • 52 Week High
  • LEXX $3.28
  • VCIG $4,644.00
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 40.14
  • VCIG 54.10
  • Support Level
  • LEXX $0.88
  • VCIG $6.01
  • Resistance Level
  • LEXX $1.01
  • VCIG $7.22
  • Average True Range (ATR)
  • LEXX 0.12
  • VCIG 0.83
  • MACD
  • LEXX -0.06
  • VCIG -0.42
  • Stochastic Oscillator
  • LEXX 3.11
  • VCIG 6.26

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

Share on Social Networks: